In the current analysis, which including 126 Ph-B-ALL patients, IKZF1 deletion was found to be related to poor OS in the group of patients who did not receive HSCT (2-year OS: 17.9 ± 11% vs. 62.6 ± 6.3%, P=0.037). The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.